Join the Symjepi group to help and get support from people like you.
Symjepi News
Many Kids Unnecessarily Hospitalized Following Allergic Reactions
FRIDAY, June 27, 2025 — Many kids are spending a lot of unnecessary time under observation in a hospital following a sudden allergic emergency, a new study concludes. About 17% of kids are admitted f...
ACAAI: Many Anaphylaxis Protocols Are Incomplete, Outdated
FRIDAY, Oct. 25, 2024 – Many anaphylaxis protocols are incomplete and/or outdated, and there is a need for patient education regarding treatment of anaphylaxis, according to two studies presented at...
Epinephrine: Tips to the 'EpiPen' Ingredient and How It Treats Anaphylaxis
TUESDAY, Oct. 8, 2024 --- The recent approval of a new epinephrine nasal spray, Neffy, gives patients a powerful new way to keep life-threatening allergic reactions at bay. But that doesn't mean...
Monthly News Roundup - August 2024
FDA Clears Pfizer and Moderna 2024-2025 COVID-19 mRNA Vaccines On August 22, the FDA approved the latest COVID-19 mRNA monovalent vaccines from Moderna (Spikevax) and Pfizer / BioNTech (Comirnaty) ...
FDA Medwatch Alert: Spectrum Laboratory Products, Inc. Issues Voluntary Worldwide Recall of Epinephrine (L-Adrenaline) USP Bulk Active Pharmaceutical Ingredient (API) Due to Discoloration of Product
January 9, 2023 – Spectrum Laboratory Products, Inc. is voluntarily recalling three lots of Epinephrine (L-Adrenaline) USP, a bulk active pharmaceutical ingredient (API) used to manufacture or...
FDA Medwatch Alert: Adamis Pharmaceuticals Corporation Issues Nationwide Voluntary Recall of Symjepi (Epinephrine) Injection for Potential Manufacturing Defect
San Diego, March 21, 2022 – Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) is voluntarily recalling certain lots of Symjepi (epinephrine) Injection 0.15 mg (0.15 mg/0.3 mL) and 0.3 mg (0.3 mg/0.3 m...
FDA Medwatch Alert: FDA Alerts Patients and Health Care Professionals that Some EpiPen Auto-Injectors May Not Readily Slide Out of Carrier Tube
[11/2/2018] FDA is alerting patients, caregivers and health care professionals that the labels attached to some EpiPen 0.3mg and EpiPen Jr 0.15mg auto-injectors, and the authorized generic versions,...
Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) – Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ lower...
Adamis Pharmaceuticals Receives FDA Approval for Symjepi (epinephrine) Pre-Filled Syringe
SAN DIEGO, June 15, 2017 (GLOBE NEWSWIRE) – Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) today announced that the U.S. Food and Drug Administration (“FDA”) has approved Adamis’ EPINEP...
Further information
Related condition support groups
Anaphylaxis, Allergic Reactions